These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10873066)

  • 1. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
    Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
    Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
    Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
    Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
    Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
    Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
    Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
    Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity.
    Mukhopadhaya A; Mendecki J; Dong X; Liu L; Kalnicki S; Garg M; Alfieri A; Guha C
    Cancer Res; 2007 Aug; 67(16):7798-806. PubMed ID: 17699785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.
    Nguyen MC; Tu GH; Koprivnikar KE; Gonzalez-Edick M; Jooss KU; Harding TC
    Cancer Immunol Immunother; 2010 Sep; 59(9):1313-23. PubMed ID: 20499060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
    Small EJ; Fratesi P; Reese DM; Strang G; Laus R; Peshwa MV; Valone FH
    J Clin Oncol; 2000 Dec; 18(23):3894-903. PubMed ID: 11099318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.
    Barrou B; Benoît G; Ouldkaci M; Cussenot O; Salcedo M; Agrawal S; Massicard S; Bercovici N; Ericson ML; Thiounn N
    Cancer Immunol Immunother; 2004 May; 53(5):453-60. PubMed ID: 14760510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
    Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
    Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
    Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
    Higano CS; Corman JM; Smith DC; Centeno AS; Steidle CP; Gittleman M; Simons JW; Sacks N; Aimi J; Small EJ
    Cancer; 2008 Sep; 113(5):975-84. PubMed ID: 18646045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
    Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
    Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
    Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.